By Associate Professor Fatima Valdes Mora

Book Chapters

Valdés-Mora F; Stirzaker C, 2018, 'Epigenetic Alterations in Primary Prostate Cancer', in Precision Molecular Pathology of Prostate Cancer, Springer Nature, pp. 193 - 211, http://dx.doi.org/10.1007/978-3-319-64096-9_13

Valdes-Mora F; Lee HJ, 2016, 'Single-Cell Genomics and Epigenomics', in Tseng FG; Santra TS (ed.), Essentials of Single-Cell Analysis Concepts, Applications and Future Prospects, SPRINGER-VERLAG BERLIN, pp. 257 - 301, http://dx.doi.org/10.1007/978-3-662-49118-8_10

Journal articles

Fernandez KJ; Sultani G; Nobis M; Gloss B; Eshraghi L; McCart Reed AE; Alexandrou S; Lee C; Roden DL; Jones EI; Simad MH; Millar EKA; Bartonicek N; Oakes SR; Valdes-Mora F; Colino-Sanguino Y; Mok ETY; Williams HL; Kutasovic JR; Cummings MC; Stoehr J; Lee V; Harvey K; Wu S; Lakhani SR; Simpson PT; Cox TR; Ooms LM; Mitchell CA; Salomon R; Swarbrick A; Gallego-Ortega D; Lim E; Timpson P; Caldon CE, 2026, 'Endocrine therapy reprogramming of breast cancer facilitates metastatic escape via upregulation of P-Rex1/Rac1 signalling', Nature Communications, 17, http://dx.doi.org/10.1038/s41467-026-70683-x

de la Fuente LR; Law AMK; Rangel-Sanchez L; Venhuizen J; Steffan F; Castillo L; Anderson RL; Valdes-Mora F; Gallego-Ortega D, 2026, 'Modelling the metastatic immune microenvironment in triple-negative breast cancer', Breast Cancer Research, 28, http://dx.doi.org/10.1186/s13058-025-02186-4

Sanguino YC; Fox S; Rodriguez de la Fuente L; Cassim A; Li S; Kearney P; Jackson E; Duchatel R; Holliday H; Tsoli M; Dun M; Mora FV, 2026, 'ID #448 Epigenomic erosion and enhancer dependence in H3.3K27M diffuse midline glioma', Neuro-Oncology Pediatrics, 2, pp. wuag026.154, http://dx.doi.org/10.1093/neuped/wuag026.154

Sanguino YC; Fox S; Cassim A; Rodriguez de la Fuente L; Li S; Jackson E; Duchatel R; Holliday H; Gopalakrishnan A; Tsoli M; Ziegler D; Ortega DG; Dun M; Mora FV, 2026, 'ID #674 Unmasking Epigenomic Vulnerabilities in Diffuse Midline Glioma to Guide Epigenetic Therapy', Neuro-Oncology Pediatrics, 2, http://dx.doi.org/10.1093/neuped/wuag026.273

Holliday H; Khan A; Ehteda A; Nguyen H; Ross SE; Jayatilleke N; Gopalakrishnan A; Wang E; Sanguino YC; Kavanagh D; Guo X; Liu J; Lawrence D; Sun CX; Lehmann R; Ip CK; Lee A; Rangel-Sanchez L; Li W; Salomon R; Firestein R; Weatheritt RJ; Valdes-Mora F; Dinger ME; Phoenix TN; Mayoh C; Rayner BS; Tsoli M; Ziegler DS, 2026, 'Combined inhibition of FACT and BET disrupts transcription to suppress tumor growth in mouse models of diffuse midline glioma', Science Translational Medicine, 18, http://dx.doi.org/10.1126/scitranslmed.adr1557

Cassim A; Colino-Sanguino Y; Fox SL; Rodriguez de la Fuente L; Hartley HE; Valdes-Mora F, 2025, 'The Bermuda Triangle of paediatric brain cancers: epigenetics, developmental timing window and cell of origin', Cancer and Metastasis Reviews, 44, http://dx.doi.org/10.1007/s10555-025-10284-0

Savary C; Persson ML; Jackson ER; Vo T; Duchatel RJ; Douglas AM; de la Fuente LR; Colino-Sanguino Y; Mora FV; Dun MD, 2025, 'DMG-08. Single-Cell Analysis of ONC201 and Paxalisib Resistance Mechanisms in Diffuse Intrinsic Pontine Glioma', Neuro-Oncology Pediatrics, 1, http://dx.doi.org/10.1093/neuped/wuaf001.038

Kisswani D; Carroll C; Valdes-Mora F; Rutar M, 2025, 'Epigenetic Alterations in Age-Related Macular Degeneration: Mechanisms and Implications', International Journal of Molecular Sciences, 26, http://dx.doi.org/10.3390/ijms26157601

Lassaletta A; Vazquez-Gomez F; Castellano S; Perez-Somarriba M; Rubio A; Gonzalez-Murillo A; Horcajo-Morera B; Bautista F; Garcia-Aguilera G; Castillo A; Solís I; Borrego P; Valdes-Mora F; Saiz-Ladera C; Melen G; Garcia-Castro J; Ramirez M, 2025, 'MDB-27. PHASE IB CLINICAL TRIAL ASSESSING SAFETY, TOLERABILITY, AND PRELIMINARY EFFICACY OF ALOCELYVIR (ALLOGENEIC MESENCHYMAL CELLS + ONCOLYTIC ADENOVIRUS) IN PEDIATRIC PATIENTS WITH RECURRENT/PROGRESSIVE MEDULOBLASTOMA', Neuro-Oncology Pediatrics, 1, http://dx.doi.org/10.1093/neuped/wuaf001.226

Cassim A; Dun MD; Gallego-Ortega D; Valdes-Mora F, 2024, 'EZHIP's role in diffuse midline glioma: echoes of oncohistones?', Trends in Cancer, 10, pp. 1095 - 1105, http://dx.doi.org/10.1016/j.trecan.2024.09.002

Colino-Sanguino Y; Rodriguez de la Fuente L; Gloss B; Law AMK; Handler K; Pajic M; Salomon R; Gallego-Ortega D; Valdes-Mora F, 2024, 'Performance comparison of high throughput single-cell RNA-Seq platforms in complex tissues', Heliyon, 10, http://dx.doi.org/10.1016/j.heliyon.2024.e37185

Duchatel RJ; Jackson ER; Parackal SG; Kiltschewskij D; Findlay IJ; Mannan A; Staudt DE; Thomas BC; Germon ZP; Laternser S; Kearney PS; Jamaluddin MFB; Douglas AM; Beitaki T; McEwen HP; Persson ML; Hocke EA; Jain V; Aksu M; Manning EE; Murray HC; Verrills NM; Sun CX; Daniel P; Vilain RE; Skerrett-Byrne DA; Nixon B; Hua S; de Bock CE; Colino-Sanguino Y; Valdes-Mora F; Tsoli M; Ziegler DS; Cairns MJ; Raabe EH; Vitanza NA; Hulleman E; Phoenix TN; Koschmann C; Alvaro F; Dayas CV; Tinkle CL; Wheeler H; Whittle JR; Eisenstat DD; Firestein R; Mueller S; Valvi S; Hansford JR; Ashley DM; Gregory SG; Kilburn LB; Nazarian J; Cain JE; Dun MD, 2024, 'PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma', Journal of Clinical Investigation, 134, pp. e170329, http://dx.doi.org/10.1172/JCI170329

Ajuyah P; Mayoh C; Lau LMS; Barahona P; Wong M; Chambers H; Valdes-Mora F; Senapati A; Gifford AJ; D’Arcy C; Hansford JR; Manoharan N; Nicholls W; Williams MM; Wood PJ; Cowley MJ; Tyrrell V; Haber M; Ekert PG; Ziegler DS; Khuong-Quang DA, 2023, 'Histone H3-wild type diffuse midline gliomas with H3K27me3 loss are a distinct entity with exclusive EGFR or ACVR1 mutation and differential methylation of homeobox genes', Scientific Reports, 13, pp. 3775, http://dx.doi.org/10.1038/s41598-023-30395-4

Jackson E; Duchatel R; Staudt D; Persson M; Mannan A; Yadavilli S; Parackal S; Game S; Chong WC; Jayasekara WS; Grand ML; Kearney P; Douglas A; Findlay I; Germon Z; McEwen H; Beitaki T; Patabendige A; Skerrett-byrne D; Nixon B; Smith N; Day B; Manoharan N; Nagabushan S; Hansford J; Govender D; McCowage G; Firestein R; Howlett M; Endersby R; Gottardo N; Alvaro F; Waszak S; Larsen M; Sanguino YC; Valdes-Mora F; Rakotomalala A; Meignan S; Pasquier E; Andre N; Hulleman E; Eisenstat D; Vitanza N; Nazarian J; Koschmann C; Mueller S; Cain J; Dun M, 2023, 'EXTH-36. COMBINING ONC201 AND PAXALISIB FOR THE TREATMENT OF DIFFUSE MIDLINE GLIOMA (DMG); THE PRECLINICAL RESULTS UNDERPINNING THE INTERNATIONAL PHASE II CLINICAL TRIAL (NCT05009992)', Neuro-Oncology, 25, pp. v232 - v232, http://dx.doi.org/10.1093/neuonc/noad179.0889

Jackson ER; Duchatel RJ; Staudt DE; Persson ML; Mannan A; Yadavilli S; Parackal S; Game S; Chong WC; Jayasekara WNS; Le Grand M; Kearney PS; Douglas AM; Findlay IJ; Germon ZP; McEwen HP; Beitaki TS; Patabendige A; Skerrett-Byrne DA; Nixon B; Smith ND; Day B; Manoharan N; Nagabushan S; Hansford JR; Govender D; McCowage GB; Firestein R; Howlett M; Endersby R; Gottardo NG; Alvaro F; Waszak SM; Larsen MR; Colino-Sanguino Y; Valdes-Mora F; Rakotomalala A; Meignan S; Pasquier E; André N; Hulleman E; Eisenstat DD; Vitanza NA; Nazarian J; Koschmann C; Mueller S; Cain JE; Dun MD, 2023, 'ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma', Cancer Research, 83, pp. 2421 - 2437, http://dx.doi.org/10.1158/0008-5472.CAN-23-0186

Jackson ER; Duchatel RJ; Staudt DE; Persson ML; Mannan A; Yadavilli S; Parackal S; Game S; Chong WC; Jayasekara WSN; Le Grand M; Kearney PS; Douglas AM; Findlay IJ; Germon ZP; McEwen HP; Beitaki TS; Patabendige A; Skerrett-Byrne DA; Nixon B; Smith ND; Day B; Manoharan N; Nagabushan S; Hansford JR; Govender D; McCowage GB; Firestein R; Howlett M; Endersby R; Gottardo NG; Alvaro F; Waszak SM; Larsen MR; Colino-Sanguino Y; Valdés-Mora F; Rakotomalala A; Meignan S; Pasquier E; Andre N; Hulleman E; Eisenstat DD; Vitanza NA; Nazarian J; Koschmann C; Mueller S; Cain JE; Dun MD, 2023, 'ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma.', Cancer Res, 83, pp. 2421 - 2437, http://dx.doi.org/10.1158/0008-5472.CAN-23-0186

Ganguly D; Schmidt MO; Coleman M; Ngo TVC; Sorrelle N; Dominguez ATA; Murimwa GZ; Toombs JE; Lewis C; Fang YV; Valdes-Mora F; Gallego-Ortega D; Wellstein A; Brekken RA, 2023, 'Pleiotrophin drives a prometastatic immune niche in breast cancer', Journal of Experimental Medicine, 220, http://dx.doi.org/10.1084/jem.20220610

Ganguly D; Schmidt M; Coleman M; Ngo T-V; Sorrelle N; Dominguez A; Toombs J; Lewis C; Fang Y; Mora F; Ortega D; Wellstein A; Brekken R, 2023, 'Abstract B016: Pleiotrophin drives a pro-metastatic immune niche within the breast tumor microenvironment', Cancer Research, 83, pp. b016 - b016, http://dx.doi.org/10.1158/1538-7445.metastasis22-b016

Sousa Â; Soares CP; Chin CM; Trisciuoglio D; Valdes-Mora F, 2023, 'Editorial: Epigenetic therapy against cancer: toward new molecular targets and technologies', Frontiers in Cell and Developmental Biology, 11, http://dx.doi.org/10.3389/fcell.2023.1218986

Papanicolaou M; Parker AL; Yam M; Filipe EC; Wu SZ; Chitty JL; Wyllie K; Tran E; Mok E; Nadalini A; Skhinas JN; Lucas MC; Herrmann D; Nobis M; Pereira BA; Law AMK; Castillo L; Murphy KJ; Zaratzian A; Hastings JF; Croucher DR; Lim E; Oliver BG; Mora FV; Parker BL; Gallego-Ortega D; Swarbrick A; O’Toole S; Timpson P; Cox TR, 2022, 'Temporal profiling of the breast tumour microenvironment reveals collagen XII as a driver of metastasis', Nature Communications, 13, http://dx.doi.org/10.1038/s41467-022-32255-7

Jackson E; Duchatel R; Persson M; Mannan A; Yadavilli S; Parackal S; Game S; Chong WC; Jayasekara S; Le Grand M; Kearney P; Douglas A; Findlay I; Staudt D; Germon Z; Skerrett-Byrne D; Nixon B; Smith N; Hulleman E; Day B; McCowage G; Alvaro F; Waszak S; Larsen M; Colino-Sanguino Y; Valdes-Mora F; Rakotomalala A; Meignan S; Pasquier E; Vitanza N; Nazarian J; Koschmann C; Cain J; Mueller S; Dun M, 2022, 'EXTH-12. PRECLINICAL AND CASE STUDY EXAMINATION OF THE COMBINATION OF THE CLPP AGONIST ONC201 WITH THE PI3K/AKT INHIBITOR PAXALISIB FOR THE TREATMENT OF DIFFUSE MIDLINE GLIOMA', Neuro-Oncology, 24, pp. vii211 - vii211, http://dx.doi.org/10.1093/neuonc/noac209.811

Araujo AM; Abaurrea A; Azcoaga P; López-Velazco JI; Manzano S; Rodriguez J; Rezola R; Egia-Mendikute L; Valdés-Mora F; Flores JM; Jenkins L; Pulido L; Osorio-Querejeta I; Fernández-Nogueira P; Ferrari N; Viera C; Martín-Martín N; Tzankov A; Eppenberger-Castori S; Alvarez-Lopez I; Urruticoechea A; Bragado P; Coleman N; Palazón A; Carracedo A; Gallego-Ortega D; Calvo F; Isacke CM; Caffarel MM; Lawrie CH, 2022, 'Erratum: Stromal oncostatin M cytokine promotes breast cancer progression by reprogramming the tumor microenvironment (Journal Clinical Investigation (2022) 132:7 (e148667) 10.1172/JCI148667)', Journal of Clinical Investigation, 132, http://dx.doi.org/10.1172/JCI165107

Law AMK; Chen J; Colino-Sanguino Y; Fuente LRDL; Fang G; Grimes SM; Lu H; Huang RJ; Boyle ST; Venhuizen J; Castillo L; Tavakoli J; Skhinas JN; Millar EKA; Beretov J; Rossello FJ; Tipper JL; Ormandy CJ; Samuel MS; Cox TR; Martelotto L; Jin D; Valdes-Mora F; Ji HP; Gallego-Ortega D, 2022, 'ALTEN: A High-Fidelity Primary Tissue-Engineering Platform to Assess Cellular Responses Ex Vivo', Advanced Science, 9, http://dx.doi.org/10.1002/advs.202103332

Ganguly D; Ngo TV; Coleman M; Sorrelle N; Dominguez A; Toombs J; Schmidt M; Mora FV; Ortega DG; Wellstein A; Brekken RA, 2022, 'Abstract 3144: Pleiotrophin drives a pro-metastatic immune niche within breast tumor microenvironment', Cancer Research, 82, pp. 3144 - 3144, http://dx.doi.org/10.1158/1538-7445.am2022-3144

Zandavi SM; Koch FC; Vijayan A; Zanini F; Mora FV; Ortega DG; Vafaee F, 2022, 'Disentangling single-cell omics representation with a power spectral density-based feature extraction', Nucleic Acids Research, 50, pp. 5482 - 5492, http://dx.doi.org/10.1093/nar/gkac436

Dun MD; Jackson ER; Duchatel RJ; Persson ML; Mannan A; Yadavilli S; Parackal S; Game S; Chong WC; Jayasekara S; Le Grand M; Kearney PS; Douglas AM; Findlay IJ; Staudt D; Germon ZP; Skerrett-Byrne DA; Nixon B; Smith ND; Hulleman E; Day B; McCowage GB; Alvaro F; Waszak SM; Larsen MR; Colino-Sanguino Y; Valdes-Mora F; Rakotomalala A; Meignan S; Pasquier E; Vitanza NA; Nazarian J; Koschmann C; Cain J; Mueller S, 2022, 'DIPG-07. Preclinical and case study results underpinning the phase II clinical trial testing the combination of ONC201 and paxalisib for the treatment of patients with diffuse midline glioma (NCT05009992)', Neuro-Oncology, 24, pp. i18 - i19, http://dx.doi.org/10.1093/neuonc/noac079.064

Colino-Sanguino Y; Clark SJ; Valdes-Mora F, 2022, 'Erratum: The H2A.Z-nucleosome code in mammals: emerging functions (Trends in Genetics (2022) 38(3) (273–289), (S0168952521002870), (10.1016/j.tig.2021.10.003)): (Trends in Genetics, 38:3 p:273–289, 2022)', Trends in Genetics, 38, pp. 516, http://dx.doi.org/10.1016/j.tig.2022.02.004

Araujo AM; Abaurrea A; Azcoaga P; López-Velazco JI; Manzano S; Rodriguez J; Rezola R; Egia-Mendikute L; Valdés-Mora F; Flores JM; Jenkins L; Pulido L; Osorio-Querejeta I; Fernández-Nogueira P; Ferrari N; Viera C; Martín-Martín N; Tzankov A; Eppenberger-Castori S; Alvarez-Lopez I; Urruticoechea A; Bragado P; Coleman N; Palazón A; Carracedo A; Gallego-Ortega D; Calvo F; Isacke CM; Caffarel MM; Lawrie CH, 2022, 'Stromal oncostatin M cytokine promotes breast cancer progression by reprogramming the tumor microenvironment', Journal of Clinical Investigation, 132, http://dx.doi.org/10.1172/JCI148667

Colino-Sanguino Y; Clark SJ; Valdes-Mora F, 2022, 'The H2A.Z-nuclesome code in mammals: emerging functions', Trends in Genetics, 38, pp. 273 - 289, http://dx.doi.org/10.1016/j.tig.2021.10.003

Rodriguez de la Fuente L; Law AMK; Gallego-Ortega D; Valdes-Mora F, 2021, 'Tumor dissociation of highly viable cell suspensions for single-cell omic analyses in mouse models of breast cancer', STAR Protocols, 2, http://dx.doi.org/10.1016/j.xpro.2021.100841

Law AMK; Rodriguez de la Fuente L; Grundy TJ; Fang G; Valdes-Mora F; Gallego-Ortega D, 2021, 'Advancements in 3D Cell Culture Systems for Personalizing Anti-Cancer Therapies', Frontiers in Oncology, 11, http://dx.doi.org/10.3389/fonc.2021.782766

Valdés-Mora F; Salomon R; Gloss BS; Law AMK; Venhuizen J; Castillo L; Murphy KJ; Magenau A; Papanicolaou M; Rodriguez de la Fuente L; Roden DL; Colino-Sanguino Y; Kikhtyak Z; Farbehi N; Conway JRW; Sikta N; Oakes SR; Cox TR; O'Donoghue SI; Timpson P; Ormandy CJ; Gallego-Ortega D, 2021, 'Single-cell transcriptomics reveals involution mimicry during the specification of the basal breast cancer subtype', Cell Reports, 35, http://dx.doi.org/10.1016/j.celrep.2021.108945

Ganguly D; Sorrelle N; Dominguez A; Toombs J; Schmidt M; Mora FV; Ortega DG; Wellstein A; Brekken RA, 2021, 'Abstract LT010: Pleiotrophin drives pro-metastatic immune niche within breast tumor microenvironment', Cancer Research, 81, pp. lt010 - lt010, http://dx.doi.org/10.1158/1538-7445.tme21-lt010

Khoury A; Achinger-Kawecka J; Bert SA; Smith GC; French HJ; Luu PL; Peters TJ; Du Q; Parry AJ; Valdes-Mora F; Taberlay PC; Stirzaker C; Statham AL; Clark SJ, 2020, 'Constitutively bound CTCF sites maintain 3D chromatin architecture and long-range epigenetically regulated domains', Nature Communications, 11, http://dx.doi.org/10.1038/s41467-019-13753-7

Achinger-Kawecka J; Valdes-Mora F; Luu PL; Giles KA; Caldon CE; Qu W; Nair S; Soto S; Locke WJ; Yeo-Teh NS; Gould CM; Du Q; Smith GC; Ramos IR; Fernandez KF; Hoon DS; Gee JMW; Stirzaker C; Clark SJ, 2020, 'Epigenetic reprogramming at estrogen-receptor binding sites alters 3D chromatin landscape in endocrine-resistant breast cancer', Nature Communications, 11, pp. 320, http://dx.doi.org/10.1038/s41467-019-14098-x

Salomon R; Martelotto L; Valdes-Mora F; Gallego-Ortega D, 2020, 'Genomic Cytometry and New Modalities for Deep Single-Cell Interrogation', Cytometry Part A, 97, pp. 1007 - 1016, http://dx.doi.org/10.1002/cyto.a.24209

Salazar-Roa M; Trakala M; Álvarez-Fernández M; Valdés-Mora F; Zhong C; Muñoz J; Yu Y; Peters TJ; Graña-Castro O; Serrano R; Zapatero-Solana E; Abad M; Bueno MJ; de Cedrón MG; Fernández-Piqueras J; Serrano M; Blasco MA; Wang DZ; Clark SJ; Izpisua-Belmonte JC; Ortega S; Malumbres M, 2020, 'Transient exposure to miR-203 enhances the differentiation capacity of established pluripotent stem cells', EMBO Journal, 39, http://dx.doi.org/10.15252/embj.2019104324

Law AMK; Valdes-Mora F; Gallego-Ortega D, 2020, 'Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer', Cells, 9, http://dx.doi.org/10.3390/cells9030561

Colino-Sanguino Y; Cornett EM; Moulder D; Smith GC; Hrit J; Cordeiro-Spinetti E; Vaughan RM; Krajewski K; Rothbart SB; Clark SJ; Valdés-Mora F, 2019, 'A Read/Write Mechanism Connects p300 Bromodomain Function to H2A.Z Acetylation', Iscience, 21, pp. 773 - 788, http://dx.doi.org/10.1016/j.isci.2019.10.053

Valdes-Mora F; Salomon R; Gloss B; Law AMK; Murphy K; Roden DL; Castillo L; Colino-Sanguino Y; Farbehi N; Conway J; Timpson P; Ormandy CJ; Gallego-Ortega D, 2019, 'Characterisation of developmental pathways that drive metastatic progression of breast cancer at single cell resolution', Oncology Abstracts, http://dx.doi.org/10.1530/oncolabs.1.p022

Salomon R; Kaczorowski D; Valdes-Mora F; Nordon RE; Neild A; Farbehi N; Bartonicek N; Gallego-Ortega D, 2019, 'Droplet-based single cell RNAseq tools: A practical guide', Lab on A Chip, 19, pp. 1706 - 1727, http://dx.doi.org/10.1039/c8lc01239c

Valdes-Mora F; Handler K; Law AMK; Salomon R; Oakes SR; Ormandy CJ; Gallego-Ortega D, 2018, 'Single-cell transcriptomics in cancer immunobiology: The future of precision oncology', Frontiers in Immunology, 9, http://dx.doi.org/10.3389/fimmu.2018.02582

Valdés-Mora F; Gould CM; Colino-Sanguino Y; Qu W; Song JZ; Taylor KM; Buske FA; Statham AL; Nair SS; Armstrong NJ; Kench JG; Lee KML; Horvath LG; Qiu M; Ilinykh A; Yeo-Teh NS; Gallego-Ortega D; Stirzaker C; Clark SJ; Valdes Mora F; Colino Sanguino Y; Sasidharan-Nair S, 2017, 'Acetylated histone variant H2A.Z is involved in the activation of neo-enhancers in prostate cancer', Nature Communications, 8, pp. 1346, http://dx.doi.org/10.1038/s41467-017-01393-8

Stirzaker C; Song JZ; Ng W; Du Q; Armstrong NJ; Locke WJ; Statham AL; French H; Pidsley R; Valdes-Mora F; Zotenko E; Clark SJ, 2017, 'Methyl-CpG-binding protein MBD2 plays a key role in maintenance and spread of DNA methylation at CpG islands and shores in cancer', Oncogene, 36, pp. 1328 - 1338, http://dx.doi.org/10.1038/onc.2016.297

Valdés-Mora F; Locke WJ; Bandrés E; Gallego-Ortega D; Cejas P; García-Cabezas MA; Colino-Sanguino Y; Feliú J; del Pulgar TG; Lacal JC, 2017, 'Clinical relevance of the transcriptional signature regulated by CDC42 in colorectal cancer', Oncotarget, 8, pp. 26755 - 26770, http://dx.doi.org/10.18632/oncotarget.15815

Colino-Sanguino Y; Clark SJ; Valdes-Mora F, 2016, 'H2A.Z acetylation and transcription: Ready, steady, go!', Epigenomics, 8, pp. 583 - 586, http://dx.doi.org/10.2217/epi-2016-0016

Gallego-Ortega D; Ledger A; Roden DL; Law AMK; Magenau A; Kikhtyak Z; Cho C; Allerdice SL; Lee HJ; Valdes-Mora F; Herrmann D; Salomon R; Young AIJ; Lee BY; Sergio CM; Kaplan W; Piggin C; Conway JRW; Rabinovich B; Millar EKA; Oakes SR; Chtanova T; Swarbrick A; Naylor MJ; O’Toole S; Green AR; Timpson P; Gee JMW; Ellis IO; Clark SJ; Ormandy CJ, 2015, 'ELF5 Drives Lung Metastasis in Luminal Breast Cancer through Recruitment of Gr1+ CD11b+ Myeloid-Derived Suppressor Cells', Plos Biology, 13, http://dx.doi.org/10.1371/journal.pbio.1002330

Valdés-Mora F; Clark SJ, 2015, 'Prostate cancer epigenetic biomarkers: Next-generation technologies', Oncogene, 34, pp. 1609 - 1618, http://dx.doi.org/10.1038/onc.2014.111

Back to profile page